Kezar Life Sciences Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 124.6 | 438.4 | 417.5 | 278.2 | – | 46.9 | 34.4 | 32.3 | 27.4 | – | – | |
| – | – | – | – | – | – | 26.8 | 35.5 | 41.2 | 33.0 | 15.5 | 7.3 | 9.8 | 18.3 | 14.1 | 16.0 | 18.5 | 21.8 | 21.6 | 37.5 | 47.5 | 43.3 | 17.9 | 21.9 | 18.7 | 8.9 | 7.8 | 4.0 | 3.7 | 3.9 | 2.9 | 4.2 | 0.4 | 0.3 | 0.4 | 0.3 | 0.7 | 0.8 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 122.7 | 424.1 | 405.0 | 268.7 | – | 20.2 | 11.1 | 14.2 | 2.7 | – | – | |
| – | – | – | – | – | – | -0.5% | -0.4% | -0.5% | -0.7% | -1.7% | -4.6% | -4.0% | -1.4% | -1.5% | -1.5% | -1.4% | -1.2% | -1.4% | -0.9% | -0.5% | -0.5% | -0.9% | -0.9% | -1.2% | -3.0% | -4.3% | -9.3% | -12.1% | -13.0% | -18.1% | -13.5% | -151.8% | -191.6% | -191.3% | -198.4% | -112.3% | -77.3% | |
| Margins | ||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -97.0% | 377.5% | 377.4% | 376.7% | – | -25.0% | -24.1% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,383.8% | -6,694.5% | -6,642.7% | -6,426.4% | – | -8,695.3% | -8,111.6% | -7,268.6% | -6,286.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,254.2% | -6,480.3% | -6,445.9% | -6,270.2% | – | -8,036.1% | -7,546.4% | -6,793.8% | -5,921.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,152.9% | -5,308.8% | -5,417.3% | -5,039.1% | – | -7,124.9% | -6,581.3% | -6,174.8% | -5,437.5% | – | – | |
| Returns | ||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | -23.6% | -13.5% | -17.2% | -21.3% | -25.3% | -29.4% | -36.2% | -45.0% | -30.5% | -24.2% | -26.9% | -29.6% | -31.8% | -37.1% | -43.0% | -27.7% | -24.8% | -20.5% | -22.7% | -25.3% | -29.5% | -35.5% | -40.6% | -54.3% | -59.9% | -65.4% | -71.4% | -71.6% | -76.3% | -77.1% | -74.4% | -80.0% | -69.3% | |
| – | – | – | – | -15.7% | -20.7% | -12.8% | -16.4% | -20.2% | -22.9% | -26.4% | -32.1% | -39.2% | -27.8% | -22.7% | -25.0% | -27.5% | -29.4% | -34.5% | -39.2% | -25.1% | -22.9% | -19.2% | -21.1% | -22.8% | -26.2% | -31.3% | -35.2% | -46.0% | -50.9% | -54.8% | -58.4% | -57.9% | -62.8% | -64.9% | -63.1% | -73.1% | -66.5% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | -102 | -40 | – | -12 | -12 | -19 | -14 | -20 | -16 | -12 | -20 | -22 | -25 | -56 | -52 | -28 | -94 | -53 | -28 | -24 | -15 | -14 | -22 | -20 | -15 | -21 | -28 | -24 | -19 | -26 | -70 | -65 | |
| 94.1% | – | – | – | -47.4% | 87.4% | 95.0% | 94.9% | 94.9% | 90.3% | 89.9% | 88.7% | 87.2% | 91.1% | 94.1% | 93.2% | 92.8% | 92.3% | 93.0% | 91.3% | 90.3% | 92.2% | 93.7% | 92.9% | 90.1% | 88.8% | 88.2% | 86.6% | 84.8% | 84.9% | 83.8% | 81.7% | 80.8% | 82.3% | 84.1% | 84.9% | 91.4% | 95.9% | |
| – | – | – | – | – | – | 0.0 | 0.0 | – | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.0 | 0.0 | |
| Per Share | ||||||||||||||||||||||||||||||||||||||
| – | – | – | -1.17 | -0.65 | -0.62 | -0.87 | -1.04 | -1.22 | -1.36 | -1.46 | -1.64 | -1.83 | -0.73 | -0.89 | -0.81 | -0.83 | -0.88 | -0.93 | -0.99 | -0.98 | -0.95 | -0.95 | -0.89 | -0.94 | -1.03 | -1.14 | -1.21 | -1.40 | -1.39 | -1.35 | -1.31 | -11.47 | -10.76 | -9.68 | -8.43 | -7.66 | -6.16 | |
| – | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.02 | 0.02 | 0.02 | -0.07 | 0.14 | 0.14 | 0.14 | 0.14 | 0.00 | – | |
| – | 0.83 | – | – | -1.97 | 2.64 | 6.46 | 6.02 | 5.72 | 5.36 | 4.96 | 4.53 | 4.08 | 2.40 | 3.69 | 3.01 | 2.82 | 2.75 | 2.50 | 2.30 | 3.52 | 3.83 | 4.63 | 3.92 | 3.74 | 3.49 | 3.21 | 2.97 | 2.58 | 2.32 | 2.07 | 1.84 | 16.02 | 14.11 | 12.55 | 11.33 | 9.58 | 8.88 | |
| – | – | – | – | -0.65 | -0.58 | -0.86 | -0.95 | -1.15 | -1.30 | -1.32 | -1.51 | -1.59 | -0.63 | -0.79 | -0.70 | -0.74 | -0.73 | -0.77 | -0.78 | -0.76 | -0.79 | -0.76 | -0.77 | -0.84 | -0.94 | -1.07 | -1.11 | -1.15 | -1.17 | -1.09 | -1.05 | -10.17 | -9.39 | -8.80 | -7.74 | -7.08 | -5.72 | |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.